LEADER 03976nam 2200997z- 450 001 9910566486303321 005 20231214132948.0 035 $a(CKB)5680000000037516 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/80940 035 $a(EXLCZ)995680000000037516 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (178 p.) 311 $a3-0365-3641-8 311 $a3-0365-3642-6 330 $aThis e-book summarises the latest advances in the rheumatic diseases with a focus on the recent efforts of vascular and pulmonary manifestations and anticipate the new and future directions of these research topic. Rheumatic diseases represent a heterogeneous group of severe autoimmune disorders. The present Special Issue aims to provide an overview of the complexity of vascular and pulmonary manifestations of rheumatologic diseases and helps in knowledge to manage them. The eleven published articles here collected underline the complexity of rheumatic diseases and the difficult to treated them. The manuscripts provide an overview of the pathophysiology and current treatment regimes of these disorders, highlighting tools which assist with diagnosis, risk stratification and therapy. Finally, we underline the importance of a multidisciplinary team working using the skills of clinicians, radiologists, and pathologists. 517 $aRheumatic Diseases 606 $aMedicine$2bicssc 606 $aPharmacology$2bicssc 610 $asystemic sclerosis 610 $ascleroderma 610 $ainterstitial lung disease 610 $apulmonary function tests 610 $ahigh-resolution computed tomography 610 $arheumatic 610 $apulmonary arterial hypertension 610 $atargeted therapy 610 $asystemic lupus erythematosus 610 $aairway disease 610 $ashrinking lung syndrome 610 $adiffuse alveolar hemorrhage 610 $apleurisy 610 $ainfection 610 $acardiopulmonary exercise testing 610 $aosteopontin 610 $aconnective tissue diseases 610 $apulmonary involvement 610 $amicrovascular involvement 610 $anailfold capillaroscopy 610 $arheumatoid arthritis 610 $ainterstitial lung diseases 610 $aCX3CL1/fractalkine 610 $aCX3CR1 610 $aM1 macrophage 610 $aM2 macrophage 610 $aSKG mice 610 $aheart failure 610 $a3D-echocardiography 610 $aventricular function 610 $aoutcome 610 $aventricular-arterial coupling 610 $aantifibrotic agents 610 $aCOVID-19 610 $aIPF 610 $aprogressive fibrosing ILD 610 $aUIP 610 $apharmacological interactions 610 $afibromyalgia 610 $agastrointestinal symptoms 610 $aprobiotic 610 $aVSL#3® 610 $aefficacy 610 $atolerability 610 $apolymyalgia rheumatica 610 $avagus nerve stimulation 610 $ainflammatory response 610 $aPMR 610 $at-vns 615 7$aMedicine 615 7$aPharmacology 700 $aRuaro$b Barbara$4edt$01322436 702 $aSalton$b Francesco$4edt 702 $aConfalonieri$b Paola$4edt 702 $aRuaro$b Barbara$4oth 702 $aSalton$b Francesco$4oth 702 $aConfalonieri$b Paola$4oth 906 $aBOOK 912 $a9910566486303321 996 $aRheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations$93035001 997 $aUNINA